La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Xenon Pharmaceuticals Croissance future
Future contrôle des critères 2/6
Xenon Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 18.6% et de 73.5% par an respectivement. Le BPA devrait croître de de 21.9% par an. Le rendement des capitaux propres devrait être -56.8% dans 3 ans.
Informations clés
18.6%
Taux de croissance des bénéfices
21.9%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 30.2% |
Taux de croissance des recettes | 73.5% |
Rendement futur des capitaux propres | -56.8% |
Couverture par les analystes | Good |
Dernière mise à jour | 13 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Aug 09Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?
Aug 09Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Jul 05We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?
Mar 16Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 47 | -337 | -283 | -291 | 11 |
12/31/2025 | 6 | -289 | -240 | -264 | 15 |
12/31/2024 | 0 | -241 | -207 | -204 | 15 |
6/30/2024 | N/A | -199 | -157 | -154 | N/A |
3/31/2024 | N/A | -189 | -158 | -154 | N/A |
12/31/2023 | N/A | -182 | -151 | -145 | N/A |
9/30/2023 | N/A | -175 | -150 | -143 | N/A |
6/30/2023 | 0 | -165 | -137 | -131 | N/A |
3/31/2023 | 1 | -148 | -119 | -114 | N/A |
12/31/2022 | 9 | -126 | -101 | -98 | N/A |
9/30/2022 | 13 | -113 | -88 | -86 | N/A |
6/30/2022 | 21 | -91 | -73 | -71 | N/A |
3/31/2022 | 23 | -83 | -69 | -67 | N/A |
12/31/2021 | 18 | -81 | -72 | -70 | N/A |
9/30/2021 | 20 | -66 | -64 | -62 | N/A |
6/30/2021 | 18 | -59 | -61 | -58 | N/A |
3/31/2021 | 29 | -37 | -58 | -56 | N/A |
12/31/2020 | 32 | -29 | -51 | -48 | N/A |
9/30/2020 | 30 | -28 | -18 | -15 | N/A |
6/30/2020 | 27 | -28 | -13 | -11 | N/A |
3/31/2020 | 14 | -38 | -11 | -9 | N/A |
12/31/2019 | 7 | -42 | -6 | -5 | N/A |
9/30/2019 | 4 | -39 | -33 | -32 | N/A |
6/30/2019 | N/A | -44 | -39 | -38 | N/A |
3/31/2019 | N/A | -42 | -36 | -35 | N/A |
12/31/2018 | N/A | -34 | -35 | -35 | N/A |
9/30/2018 | 0 | -34 | -35 | -34 | N/A |
6/30/2018 | 0 | -27 | -30 | -29 | N/A |
3/31/2018 | 0 | -27 | N/A | -30 | N/A |
12/31/2017 | 0 | -31 | N/A | -29 | N/A |
9/30/2017 | 1 | -29 | N/A | -27 | N/A |
6/30/2017 | 1 | -29 | N/A | -22 | N/A |
3/31/2017 | 1 | -27 | N/A | -21 | N/A |
12/31/2016 | 2 | -23 | N/A | -20 | N/A |
9/30/2016 | 5 | -21 | N/A | -20 | N/A |
6/30/2016 | 9 | -17 | N/A | -21 | N/A |
3/31/2016 | 12 | -10 | N/A | -17 | N/A |
12/31/2015 | 16 | -16 | N/A | -18 | N/A |
9/30/2015 | 17 | -2 | N/A | -16 | N/A |
6/30/2015 | 26 | 5 | N/A | -5 | N/A |
3/31/2015 | 27 | 4 | N/A | -4 | N/A |
12/31/2014 | 28 | 13 | N/A | 0 | N/A |
9/30/2014 | 29 | 6 | N/A | 1 | N/A |
6/30/2014 | 27 | 4 | N/A | -1 | N/A |
3/31/2014 | 27 | 4 | N/A | -1 | N/A |
12/31/2013 | 27 | 4 | N/A | -3 | N/A |
9/30/2013 | 25 | 0 | N/A | 19 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: XENE devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: XENE devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: XENE devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de XENE ( 73.5% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de XENE ( 73.5% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: XENE devrait être non rentable dans 3 ans.